| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) through any online brokerage.
Other companies in Eupraxia Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Eupraxia Pharmaceuticals has a consensus price target of $16.33.
The stock price for Eupraxia Pharmaceuticals (NASDAQ: EPRX) is $7.65 last updated October 6, 2026 at 5:11 AM EDT.
There are no upcoming dividends for Eupraxia Pharmaceuticals.
Eupraxia Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Eupraxia Pharmaceuticals.
Eupraxia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
